Thomas Leggett
Known title: Chief Financial OfficerCIK: 0001774690
Associated companies
Transaction History
| STOK | ▼ Sell | Open Market | 2,173 | $68K | 3/18/2026 | View on chart |
| STOK | ▼ Sell | Open Market | 172 | $5K | 3/18/2026 | View on chart |
| STOK | ▼ Sell | Open Market | 37 | $1K | 3/18/2026 | View on chart |
| STOK | ▼ Sell | Open Market | 1,274 | $42K | 3/17/2026 | View on chart |
| STOK | ▼ Sell | Open Market | 922 | $31K | 3/17/2026 | View on chart |
| STOK | ▲ Buy | Option Exercise | 14,750 | $0 | 3/15/2026 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 13, 2026
Stoke Therapeutics presents STK-002 data at AAO 2026 meeting
Stoke Therapeutics presented new data on its investigational drug STK-002 at the American Academy of Ophthalmology 2026 annual meeting. The data suggest the therapy may have disease-modifying potential for autosomal dominant optic atrophy. In a separate update, the company noted FDA alignment on endpoint criteria for its Zorevunersen program, which could affect future trial design.
Stoke Therapeutics presents STK-002 data at AAO 2026 meeting. Stoke Therapeutics presented new data on its investigational drug STK-002 at the American Academy of Ophthalmology 2026 annual meeting. The data suggest the therapy may have disease-modifying potential for autosomal dominant optic atrophy. In a separate update, the company noted FDA alignment on endpoint criteria for its Zorevunersen program, which could affect future trial design.